Transcept Pharmaceuticals, Inc. (Transcept) is a specialty pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience. In November 2011, the United States Food and Drug Administration (FDA) approved its new drug application (NDA) for Intermezzo (zolpidem tartrate) sublingual tablet C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. In March 2011, the Company began a Phase II study of TO-2061, a low dose of ondansetron adjunctive treatment for patients with obsessive compulsive disorder (OCD), who has not adequately responded to first-line therapy.